Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Stock analysts at Zacks Research dropped their Q3 2026 EPS estimates for shares of Oramed Pharmaceuticals in a note issued to investors on Friday, August 28th. Zacks Research analyst M. Marin now anticipates that the biotechnology company will post earnings per share of $0.43 for the quarter, down from their prior estimate of $0.52. The consensus estimate for Oramed Pharmaceuticals' current full-year earnings is $1.24 per share. Zacks Research also issued estimates for Oramed Pharmaceuticals' Q4 2026 earnings at $0.37 EPS and FY2026 earnings at $3.40 EPS.
Several other equities research analysts have also weighed in on the company. Wall Street Zen upgraded Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Oramed Pharmaceuticals currently has a consensus rating of "Hold".
Check Out Our Latest Analysis on ORMP
Oramed Pharmaceuticals Stock Performance
ORMP opened at $4.85 on Wednesday. The company has a market cap of $201.75 million, a PE ratio of 1.18 and a beta of 1.22. The stock has a 50-day moving average of $4.44 and a 200-day moving average of $3.97. Oramed Pharmaceuticals has a 52-week low of $2.09 and a 52-week high of $5.47.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.52).
Hedge Funds Weigh In On Oramed Pharmaceuticals
Several large investors have recently added to or reduced their stakes in the company. SB Capital Management Inc bought a new stake in shares of Oramed Pharmaceuticals in the 4th quarter worth approximately $5,415,000. Marshall Wace LLP bought a new position in Oramed Pharmaceuticals in the fourth quarter worth $738,000. Ritholtz Wealth Management acquired a new stake in Oramed Pharmaceuticals during the first quarter worth $529,000. Hillsdale Investment Management Inc. bought a new stake in Oramed Pharmaceuticals in the 1st quarter valued at $331,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Oramed Pharmaceuticals during the 2nd quarter valued at about $381,000. Institutional investors and hedge funds own 12.73% of the company's stock.
Insider Activity at Oramed Pharmaceuticals
In other Oramed Pharmaceuticals news, COO Joshua Hexter sold 137,000 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total value of $611,020.00. Following the completion of the sale, the chief operating officer directly owned 1,023,384 shares of the company's stock, valued at $4,564,292.64. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Avraham Gabay sold 73,360 shares of the firm's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.51, for a total transaction of $330,853.60. Following the completion of the sale, the chief financial officer owned 671,785 shares in the company, valued at $3,029,750.35. This represents a 9.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 20.77% of the company's stock.
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed's platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.
The company's lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
